US · OMDA · MEDICAL - HEALTHCARE INFORMATION SERVICES
Omada Health (OMDA) intrinsic value and stock valuation
$11.87as of 2026-11-21 · Mkt cap 1.41B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Omada Health DCF and intrinsic value
InvestorsCraft values OMDA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from OMDA’s statements →
Omada Health Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2022–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- 10x Genomics, Inc. (TXG) $51.80
- UFP Technologies, Inc. (UFPT) $290.85
- BioCryst Pharmaceuticals, Inc. (BCRX) $7.22
- Progyny, Inc. (PGNY) $35.71
- Omnicell, Inc. (OMCL) $32.51
- Maze Therapeutics, Inc. (MAZE) $31.37
- Xeris Biopharma Holdings, Inc. (XERS) $16.97
- Schrödinger, Inc. (SDGR) $22.93
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $260.2M | $169.8M | $122.8M | $89.2M |
| Operating income | -$-11.97M | -$-43.65M | -$-66M | -$-72.35M |
| Net income | -$-12.78M | -$-47.14M | -$-67.51M | -$-72.52M |
| EPSd | -$-218.72K | -$-845.71K | -$-1.21M | -$-1.3M |
| Operating cash flow | $18.3M | -$-34.18M | -$-49.74M | -$-68.98M |
| Capital expenditure | -$-1.32M | -$-3.86M | -$-2.92M | -$-2.72M |
| Free cash flow | $16.9M | -$-38.04M | -$-52.66M | -$-71.7M |
| Total assets | $305.4M | $150.9M | $175.1M | $221.8M |
| Total debt | $0.00 | $30.2M | $30.6M | $30.8M |
| Net debt | -$-222.04M | -$-46.21M | -$-85.06M | -$-137.31M |
| Total equity | $229.7M | $64.6M | $98.9M | $155.6M |
| Cash and short-term investments | $222M | $76.4M | $115.6M | $168.1M |
Income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $260.2M | $169.8M | $122.8M | $89.2M |
| Cost of revenue | $89.3M | $66.9M | $52.8M | $46.4M |
| Gross profit | $170.9M | $102.9M | $70M | $42.8M |
| Research and development expenses | $40.7M | $35.9M | $33.7M | $26.2M |
| Selling, general and administrative expenses | $142.2M | $110.6M | $102.2M | $89M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $182.9M | $146.5M | $136M | $115.1M |
| Cost and expenses | $272.2M | $213.5M | $188.8M | $161.5M |
| Interest income | $5.3M | $810K | $5.78M | $2.2M |
| Interest expense | $2.53M | $4.51M | $4.71M | $4.2M |
| Depreciation and amortization | $5.49M | $4.8M | $4.45M | $4.33M |
| Ebitda | -$-4.75M | -$-37.83M | -$-58.36M | -$-63.99M |
| Operating income | -$-11.97M | -$-43.65M | -$-66M | -$-72.35M |
| Total other income/expenses, net | -$-810K | -$-3.48M | -$-1.51M | -$-170K |
| Income before tax | -$-12.78M | -$-47.14M | -$-67.51M | -$-72.52M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-12.78M | -$-47.14M | -$-67.51M | -$-72.52M |
| Weighted average shares outstanding | $58.4M | $55.7M | $55.7M | $55.7M |
| Weighted average diluted shares outstanding | $58.4M | $55.7M | $55.7M | $55.7M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Cash and short-term investments | $222M | $76.4M | $115.6M | $168.1M |
| Net receivables | $34.6M | $23.9M | $16.4M | $11.7M |
| Inventory | $4.49M | $3.3M | $3.61M | $3.54M |
| Total current assets | $272.9M | $113.1M | $142.9M | $188.6M |
| Property, plant and equipment, net | $7.94M | $6.07M | $5.6M | $6.06M |
| Goodwill and intangible assets | $15.7M | $17.5M | $19.5M | $21.6M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $32.5M | $37.8M | $32.2M | $33.2M |
| Total assets | $305.4M | $150.9M | $175.1M | $221.8M |
| Accounts payable | $10.3M | $4.17M | $3.62M | $4.11M |
| Short-term debt | $0.00 | $410K | $790K | $650K |
| Deferred revenue | $25.1M | $19.5M | $14.9M | $13.4M |
| Total current liabilities | $75.7M | $54M | $43.8M | $34.5M |
| Long-term debt | $0.00 | $29.8M | $29.8M | $30.2M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $0.00 | $32.3M | $32.4M | $31.7M |
| Capital lease obligations | $0.00 | $410K | $1.2M | $1.91M |
| Total liabilities | $75.7M | $86.3M | $76.2M | $66.2M |
| Common stock | $60K | $10K | $10K | $20K |
| Retained earnings | -$-456.74M | -$-443.97M | -$-396.83M | -$-329.32M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $229.7M | $64.6M | $98.9M | $155.6M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $30.2M | $30.6M | $30.8M |
| Net debt | -$-222.04M | -$-46.21M | -$-85.06M | -$-137.31M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Net income | -$-12.78M | -$-47.14M | -$-67.51M | -$-72.52M |
| Depreciation and amortization | $5.49M | $4.8M | $4.45M | $4.33M |
| Stock-based compensation | $13M | $9.42M | $8.74M | $6.65M |
| Change in working capital | $3.74M | -$-6.57M | -$-1.5M | -$-9.14M |
| Accounts receivable | -$-12.36M | -$-8.8M | -$-5.34M | -$-3.93M |
| Inventory | -$-1.19M | $320K | -$-70K | -$-1.95M |
| Accounts payable | $6.29M | $400K | -$-290K | -$-4.99M |
| Net cash provided by operating activities | $18.3M | -$-34.18M | -$-49.74M | -$-68.98M |
| Investments in property, plant and equipment | -$-1.32M | -$-600K | -$-420K | -$-720K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-5.83M | -$-3.86M | -$-2.92M | -$-2.72M |
| Common stock issued | $169.9M | $3.33M | $1.75M | $1.74M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $133.2M | -$-1.21M | $180K | $16.3M |
| Net change in cash | $145.6M | -$-39.25M | -$-52.48M | -$-55.38M |
| Cash at end of period | $222M | $76.4M | $115.6M | $168.1M |
| Operating cash flow | $18.3M | -$-34.18M | -$-49.74M | -$-68.98M |
| Capital expenditure | -$-1.32M | -$-3.86M | -$-2.92M | -$-2.72M |
| Free cash flow | $16.9M | -$-38.04M | -$-52.66M | -$-71.7M |
Line items
Line items
Line items
About Omada Health
Omada Health is an American virtual health company that delivers evidence-based digital programs designed to manage common chronic ailments, including cardiometabolic, musculoskeletal, and behavioral health conditions, offering continuous support that bridges the gap between in-person medical appointments.
- CEO
- Sean Duffy
- Employees
- 916
- Beta
- 1.72
Explore
Frequently asked questions
What is the intrinsic value of Omada Health (OMDA)?
Omada Health (OMDA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is OMDA undervalued?
OMDA trades at a price of $11.87 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.